Key result
Higher baseline erythropoietin is linked to ~125% increased mid-term mortality after TAVR.
Why the study?
The independent prognostic roles of erythropoietin levels and anemia in severe aortic stenosis patients undergoing TAVR were not well established.
Observational (n=360)
No
Answers are grounded in this paper and cite their sources.
Background: Both EPO levels and anemia have shown prognostic value in several cardiac disorders. An observational study with a prospective follow-up was performed to investigate their independent prognostic roles in severe aortic stenosis. Methods: An up to 36-month follow-up of consecutive patients with severe aortic stenosis undergoing TAVR in a high-volume center was performed. Patients with eGRF <30 mL/min/1.73 m2 were excluded. EPO levels and/or anemia status and its association with mid-term mortality were assessed. Results: Out of 407, 360 met eligibility criteria. Median age was 83 years, with 71.4% having a NYHA class III/IV. Anemia was present in 51.9%, and iron deficiency in 52.8%. Median (IQR) EPO levels were 14.4 (9.30–24.30) mIU/mL. Median follow-up was 566 days. Anemia was associated with overall mortality (HR 2.40, 95% CI 1.51–3.80, p < 0.001). Higher logEPO levels were associated with mid-term mortality (HR 4.05, 95% CI 2.29–7.16, p < 0.001), even after adjusting for clinically and/or statistically relevant factors (multivariate HR 2.25, 95 CI 1.09–4.66, p = 0.029). Kaplan-Meier analyses showed early diverging curves for anemia vs. non-anemia, whereas curves for patients in various EPO level quartiles started to diverge at about 100 days, with differences consistently increasing during the subsequent entire follow-up period. Conclusions: Differently from anemia, which was a strong predictor for both early and late mortality in severe aortic stenosis after TAVR, independent prognostic value of EPO only emerged after post-TAVR recovery. EPO prognostic value was independent from anemia and mild-to-moderate renal dysfunction. High EPO levels could be useful to identify patients with severe aortic stenosis showing a compromised mid-term survival in spite of TAVR use and independently from early TAVR results.
No takes yet. Share an insight, caveat, or question.
Mas‐Peiró et al. (2020) conducted an observational in Severe aortic stenosis (n=360). Baseline endogenous erythropoietin (EPO) levels vs. Lower EPO levels was evaluated on Mid-term all-cause mortality (HR 2.25, 95% CI 1.09-4.66, p=0.029). Higher baseline endogenous erythropoietin levels were independently associated with increased mid-term all-cause mortality in patients with severe aortic stenosis undergoing TAVR.
Synapse has enriched 10 related papers. Consider them for comparative context: